Q-omics provides the consensus-scored CCDC162P profile across patient tissues and cancer cell-line models. CCDC162P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CCDC162P is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, CCDC162P RNA expression shows 16,604 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRP, and UVM as cancer lineages where CCDC162P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC162P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC162P survival associations across molecular data types. CCDC162P RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC162P RNA expression–survival associations across cancer types. High CCDC162P expression shows unfavorable associations in LGG and UVM, but favorable associations in BLCA, SKCM, UCS and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for CCDC162P RNA expression.
This table summarizes CCDC162P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC162P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC162P shows lower tumor expression in KIRP and KICH and higher tumor expression in HNSC, BLCA, STAD and LUSC. The KIRP box plot shows higher CCDC162P RNA expression in normal versus tumor tissue (log2 FC = −0.702, t-test p < 0.001).
This table shows molecular features associated with CCDC162P in patient tissues and cancer cell lines. In patient samples, CCDC162P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
